Galderma, a Swiss pharmaceutical company known for its skin care treatments, sees an opportunity in the “Ozempic face” phenomenon. The CEO believes that the popularity of weight-loss drugs like Ozempic could lead to an increase in demand for their facial fillers products. This is because Ozempic can cause a sunken-in look in some patients’ faces, which fillers can help to counteract.
Galderma has products like Sculptra that are designed to restore the gaunt look associated with Ozempic face. The company has also started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.
Some dermatologists have noted that “Ozempic face” has become increasingly common in their practices due to the widespread use of weight-loss medications. The term refers to the sunken and aged appearance that can result from rapid weight loss.
Galderma, which went public last month on the SIX Swiss Exchange, reported a 12.4% increase in sales year-over-year in the first quarter of the year. The company also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic.
In recent years, there has been an increase in patients seeking non-surgical solutions for facial rejuvenation, particularly those who have undergone rapid weight loss or are looking to enhance their features without going under the knife.
Galderma’s products provide an excellent solution for this growing market as they are specifically designed to address issues such as fine lines, wrinkles, and sagging skin.
The study being conducted by Galderma aims to further validate these benefits by examining how Sculptra and Restylane can improve contouring and reduce signs of aging in patients using GLP-1 treatments.
As more people turn to non-surgical options for facial rejuvenation, it is clear that Galderma is well positioned to capitalize on this trend with its innovative products and strong growth prospects.
In conclusion, Galderma’s recognition of the potential opportunity presented by “Ozempic face” demonstrates its commitment to staying at the forefront of innovation within its industry. With continued investment in research and development, Galderma is set to remain a leader in skincare solutions for years to come.